NCT02182895View on ClinicalTrials.gov

Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient

PHASE4CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions
Diabetes Mellitus
Interventions
DRUG

Saxagliptin

2.5-5 mg daily

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT02182895 - Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient | Biotech Hunter | Biotech Hunter